600285 羚锐制药
已收盘 06-18 15:00:00
资讯
新帖
简况
羚锐制药：通络祛痛膏为医保常规目录产品
证券之星 · 06-18 17:12
羚锐制药：通络祛痛膏为医保常规目录产品
羚锐制药：公司严格遵守法律法规、公司章程及《羚锐制药未来三年（2024-2026 年度）股东回报规划》相关规定
证券之星 · 06-18 17:09
羚锐制药：公司严格遵守法律法规、公司章程及《羚锐制药未来三年（2024-2026 年度）股东回报规划》相关规定
羚锐制药（600285）62.5万股限售股将于6月17日解禁，占总股本0.11%
证券之星 · 06-17
羚锐制药（600285）62.5万股限售股将于6月17日解禁，占总股本0.11%
每周股票复盘：羚锐制药（600285）完成董事会换届并召开业绩说明会
证券之星 · 05-24
每周股票复盘：羚锐制药（600285）完成董事会换届并召开业绩说明会
羚锐制药（600285）披露召开2025年年度暨2026年第一季度业绩说明会公告，5月21日股价下跌1.1%
证券之星 · 05-21
羚锐制药（600285）披露召开2025年年度暨2026年第一季度业绩说明会公告，5月21日股价下跌1.1%
羚锐制药（600285）披露选举第十届董事会职工代表董事公告，5月20日股价下跌1.18%
证券之星 · 05-20
羚锐制药（600285）披露选举第十届董事会职工代表董事公告，5月20日股价下跌1.18%
每周股票复盘：羚锐制药（600285）2025年度拟每股派现1.10元
证券之星 · 05-02
每周股票复盘：羚锐制药（600285）2025年度拟每股派现1.10元
国金证券：给予羚锐制药买入评级
证券之星 · 04-29
国金证券：给予羚锐制药买入评级
羚锐制药（600285）披露获得盐酸氮䓬斯汀鼻喷雾剂药品注册证书公告，4月28日股价上涨5.22%
证券之星 · 04-28
羚锐制药（600285）披露获得盐酸氮䓬斯汀鼻喷雾剂药品注册证书公告，4月28日股价上涨5.22%
图解羚锐制药一季报：第一季度单季净利润同比增长13.61%
证券之星 · 04-28
图解羚锐制药一季报：第一季度单季净利润同比增长13.61%
羚锐制药（600285）披露关于使用闲置自有资金进行现金管理的公告，4月27日股价下跌0.65%
证券之星 · 04-27
羚锐制药（600285）披露关于使用闲置自有资金进行现金管理的公告，4月27日股价下跌0.65%
每周股票复盘：羚锐制药（600285）获铝碳酸镁咀嚼片注册证
证券之星 · 03-29
每周股票复盘：羚锐制药（600285）获铝碳酸镁咀嚼片注册证
羚锐制药（600285）披露大股东部分股份质押公告，3月24日股价上涨0.18%
证券之星 · 03-24
羚锐制药（600285）披露大股东部分股份质押公告，3月24日股价上涨0.18%
每周股票复盘：羚锐制药（600285）羚锐集团质押3735万股占总股本6.59%
证券之星 · 03-22
每周股票复盘：羚锐制药（600285）羚锐集团质押3735万股占总股本6.59%
羚锐制药（600285）披露大股东部分股份质押公告，3月19日股价下跌0.63%
证券之星 · 03-19
羚锐制药（600285）披露大股东部分股份质押公告，3月19日股价下跌0.63%
每周股票复盘：羚锐制药（600285）大股东质押股份用于经营周转
证券之星 · 01-18
每周股票复盘：羚锐制药（600285）大股东质押股份用于经营周转
羚锐制药（600285）股东河南羚锐集团有限公司质押170万股，占总股本0.3%
证券之星 · 01-14
羚锐制药（600285）股东河南羚锐集团有限公司质押170万股，占总股本0.3%
羚锐制药（600285）发布“提质增效重回报”行动方案，1月5日股价上涨4.88%
证券之星 · 01-05
羚锐制药（600285）发布“提质增效重回报”行动方案，1月5日股价上涨4.88%
每周股票复盘：羚锐制药（600285）推“提质增效重回报”行动方案
证券之星 · 01-02
每周股票复盘：羚锐制药（600285）推“提质增效重回报”行动方案
羚锐制药（600285）披露高级管理人员辞职公告，12月30日股价上涨1.07%
证券之星 · 2025-12-30
羚锐制药（600285）披露高级管理人员辞职公告，12月30日股价上涨1.07%
加载更多
公司概况
公司名称：
河南羚锐制药股份有限公司
所属行业：
医药制造业
上市日期：
2000-10-18
主营业务：
河南羚锐制药股份有限公司的主营业务是药品的研发、生产及销售。公司的主要产品是贴剂、片剂、胶囊剂、软膏剂。2025年，公司入选“2024年度中国医药工业百强榜”。
发行价格：
8.30
{"stockData":{"symbol":"600285","market":"SH","secType":"STK","nameCN":"羚锐制药","latestPrice":20.12,"timestamp":1781766001000,"preClose":20.45,"halted":0,"volume":5463361,"delay":0,"changeRate":-0.0161,"floatShares":566000000,"shares":567000000,"eps":1.3913,"marketStatus":"已收盘","change":-0.33,"latestTime":"06-18 15:00:00","open":20.39,"high":20.41,"low":20.09,"amount":110000000,"amplitude":0.0156,"askPrice":20.13,"askSize":104,"bidPrice":20.12,"bidSize":200,"shortable":0,"etf":0,"ttmEps":1.3913,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782091800000},"marketStatusCode":5,"adr":0,"adjPreClose":20.45,"symbolType":"stock","openAndCloseTimeList":[[1781746200000,1781753400000],[1781758800000,1781766000000]],"highLimit":22.5,"lowLimit":18.41,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":567115486,"isCdr":false,"pbRate":3.13,"roa":"--","peRate":14.461295,"roe":"6.99%","epsLYR":1.34,"committee":0.725326,"marketValue":11410000000,"turnoverRate":0.0096,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-06-22。","floatMarketCap":11398000000},"requestUrl":"/m/hq/s/600285","defaultTab":"news","newsList":[{"id":"2644403709","title":"羚锐制药：通络祛痛膏为医保常规目录产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2644403709","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644403709?lang=zh_cn&edition=full","pubTime":"2026-06-18 17:12","pubTimestamp":1781773965,"startTime":"0","endTime":"0","summary":"证券之星消息，羚锐制药(600285)06月18日在投资者关系平台上答复投资者关心的问题。投资者提问：公司拳头产品通络祛痛膏是基药和医保双目录产品，因为是独家产品，未有集采。那么，该药医保支付价格是如何确定的？是一成不变还是要定期协商谈判？羚锐制药回复：尊敬的投资者，您好！通络祛痛膏为医保常规目录产品，不属于国家谈判药品和国家集采中选药品。感谢您对公司的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800029917.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","600285","BK0239","BK0077","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644709491","title":"羚锐制药：公司严格遵守法律法规、公司章程及《羚锐制药未来三年（2024-2026 年度）股东回报规划》相关规定","url":"https://stock-news.laohu8.com/highlight/detail?id=2644709491","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644709491?lang=zh_cn&edition=full","pubTime":"2026-06-18 17:09","pubTimestamp":1781773750,"startTime":"0","endTime":"0","summary":"证券之星消息，羚锐制药06月18日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，看到公司2026年一季度现金只有4.5亿。同时公司短期借款2.7亿。公司财务情况请参考公告的公司定期财务报告。公司严格遵守法律法规、公司章程及《羚锐制药未来三年股东回报规划》相关规定，并综合考虑所处行业特点、发展阶段、自身经营模式及盈利水平等因素制定分红方案。感谢您对公司的关注。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800029782.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600285","BK0188","BK0070","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644279626","title":"羚锐制药（600285）62.5万股限售股将于6月17日解禁，占总股本0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644279626","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644279626?lang=zh_cn&edition=full","pubTime":"2026-06-17 08:12","pubTimestamp":1781655179,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，羚锐制药于6月17日将有62.5万股限售股份解禁，为公司股权激励限售股份，占公司总股本0.11%。本次解禁后，公司还有62.5万股限售股份，占总股本0.11%。羚锐制药主营业务：药品的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700006786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600285","BK0070","BK0239","BK0077","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637376376","title":"每周股票复盘：羚锐制药（600285）完成董事会换届并召开业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2637376376","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637376376?lang=zh_cn&edition=full","pubTime":"2026-05-24 04:36","pubTimestamp":1779568574,"startTime":"0","endTime":"0","summary":"河南羚锐制药股份有限公司于2026年5月20日召开职工代表大会，选举陈燕女士为公司第十届董事会职工代表董事。河南羚锐制药股份有限公司于2026年5月20日在河南省新县召开2025年年度股东会，会议由董事会召集，董事长熊伟主持，采用现场与网络投票结合方式召开。河南羚锐制药股份有限公司将于2026年5月29日15:00-16:00通过上证路演中心召开2025年年度暨2026年第一季度业绩说明会，介绍公司经营成果和财务状况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400001441.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600285","BK0239","BK0077","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637337423","title":"羚锐制药（600285）披露召开2025年年度暨2026年第一季度业绩说明会公告，5月21日股价下跌1.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637337423","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637337423?lang=zh_cn&edition=full","pubTime":"2026-05-21 23:00","pubTimestamp":1779375644,"startTime":"0","endTime":"0","summary":"截至2026年5月21日收盘，羚锐制药报收于21.55元，较前一交易日下跌1.1%，最新总市值为122.21亿元。该股当日开盘21.82元，最高21.98元，最低21.53元，成交额达1.11亿元，换手率为0.9%。公告显示，公司将于2026年5月29日15:00-16:00通过上证路演中心召开2025年年度暨2026年第一季度业绩说明会，介绍公司经营成果和财务状况。投资者可于2026年5月22日至5月28日16:00前通过上证路演中心网站或公司邮箱提交问题。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100044991.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","600285","BK0070","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636825200","title":"羚锐制药（600285）披露选举第十届董事会职工代表董事公告，5月20日股价下跌1.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636825200","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636825200?lang=zh_cn&edition=full","pubTime":"2026-05-20 22:49","pubTimestamp":1779288552,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘，羚锐制药报收于21.79元，较前一交易日下跌1.18%，最新总市值为123.57亿元。公告显示，公司于2026年5月20日召开职工代表大会，选举陈燕女士为公司第十届董事会职工代表董事。陈燕女士将与公司2025年年度股东会选举产生的其他董事共同组成第十届董事会，任期自职工代表大会审议通过之日起至第十届董事会任期届满之日止。陈燕女士符合相关法律法规及公司章程规定的任职条件，未受过监管部门处罚，持有公司股份965,000股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000043629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600285","BK0070","BK0239","BK0077","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632368644","title":"每周股票复盘：羚锐制药（600285）2025年度拟每股派现1.10元","url":"https://stock-news.laohu8.com/highlight/detail?id=2632368644","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632368644?lang=zh_cn&edition=full","pubTime":"2026-05-02 02:56","pubTimestamp":1777661770,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，羚锐制药报收于22.36元，较上周的21.59元上涨3.57%。本周，羚锐制药4月30日盘中最高价报22.93元。该方案尚需提交2025年年度股东会审议通过。公司发布2025年度社会责任报告，全年实现营业收入38.53亿元，净利润7.60亿元，同比增长10.07%和5.11%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200000592.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","BK0070","600285","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631553016","title":"国金证券：给予羚锐制药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2631553016","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631553016?lang=zh_cn&edition=full","pubTime":"2026-04-29 08:47","pubTimestamp":1777423668,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司甘坛焕,王奔奔近期对羚锐制药进行研究并发布了研究报告《业绩稳健增长，分红比例提升》，给予羚锐制药买入评级。 羚锐制药 业绩简评 2026年4月27日，公司发布2025年年报。2025年公司实现收入38.5亿元，归母净利润7.6亿元，扣非归母净利润7.1亿元。银谷制药2025年实现营收约3.12亿元，净利润约5060万元。最新盈利预测明细如下：该股最近90天内共有1家机构给出评级，增持评级1家；过去90天内机构目标均价为29.9。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900027259.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600285"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630624583","title":"羚锐制药（600285）披露获得盐酸氮䓬斯汀鼻喷雾剂药品注册证书公告，4月28日股价上涨5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630624583","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630624583?lang=zh_cn&edition=full","pubTime":"2026-04-28 22:03","pubTimestamp":1777385010,"startTime":"0","endTime":"0","summary":"截至2026年4月28日收盘，羚锐制药报收于22.57元，较前一交易日上涨5.22%，最新总市值为128亿元。该股当日开盘22.34元，最高22.85元，最低22.34元，成交额达5.91亿元，换手率为4.63%。近日，羚锐制药发布《关于获得药品注册证书的公告》。公告显示，公司子公司银谷制药有限责任公司收到国家药品监督管理局核准签发的盐酸氮斯汀鼻喷雾剂《药品注册证书》。银谷制药为该品种首家过评企业，累计投入约1,079.4万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800063923.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600285","BK0239","BK0070","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630312130","title":"图解羚锐制药一季报：第一季度单季净利润同比增长13.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630312130","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630312130?lang=zh_cn&edition=full","pubTime":"2026-04-28 03:58","pubTimestamp":1777319914,"startTime":"0","endTime":"0","summary":"证券之星消息，羚锐制药2026年一季报显示，一季度公司主营收入11.26亿元，同比上升10.32%；归母净利润2.46亿元，同比上升13.61%；扣非净利润2.28亿元，同比上升11.59%；负债率38.22%，投资收益1102.61万元，财务费用-610.3万元，毛利率78.19%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800011130.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600285"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630768390","title":"羚锐制药（600285）披露关于使用闲置自有资金进行现金管理的公告，4月27日股价下跌0.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630768390","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630768390?lang=zh_cn&edition=full","pubTime":"2026-04-27 22:26","pubTimestamp":1777299960,"startTime":"0","endTime":"0","summary":"截至2026年4月27日收盘，羚锐制药报收于21.45元，较前一交易日下跌0.65%，最新总市值为121.65亿元。该股当日开盘21.59元，最高21.73元，最低21.24元，成交额达1.59亿元，换手率为1.31%。近日，羚锐制药发布《关于使用闲置自有资金进行现金管理的公告》。该事项尚需提交公司2025年年度股东会审议。公司已制定风险控制措施，确保资金安全，不影响日常经营和主营业务发展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700046623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600285","BK0239","BK0077","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623333952","title":"每周股票复盘：羚锐制药（600285）获铝碳酸镁咀嚼片注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2623333952","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623333952?lang=zh_cn&edition=full","pubTime":"2026-03-29 04:23","pubTimestamp":1774729389,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，羚锐制药报收于22.28元，较上周的22.49元下跌0.93%。本周，羚锐制药3月27日盘中最高价报22.55元。本周关注点公司公告汇总：羚锐制药获铝碳酸镁咀嚼片药品注册证书，视同通过仿制药一致性评价。羚锐集团及其一致行动人合计持股127,813,609股，累计质押37,900,000股，占公司总股本6.68%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900001068.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0188","BK0239","BK0077","600285"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621093156","title":"羚锐制药（600285）披露大股东部分股份质押公告，3月24日股价上涨0.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621093156","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621093156?lang=zh_cn&edition=full","pubTime":"2026-03-24 22:17","pubTimestamp":1774361845,"startTime":"0","endTime":"0","summary":"截至2026年3月24日收盘，羚锐制药报收于21.79元，较前一交易日上涨0.18%，最新总市值为123.57亿元。近日，羚锐制药发布《关于大股东部分股份质押的公告》。公告显示，公司大股东河南羚锐集团有限公司持有公司股份121,817,898股，占公司总股本的21.48%。本次质押550,000股后，累计质押股份37,900,000股，占其持股比例31.11%，占公司总股本6.68%。本次质押融资用途为经营流动资金周转，质权人为河南农村商业银行股份有限公司新县支行，质押起始日为2026年3月23日，至解除质押日止。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400039885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0188","600285","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621799954","title":"每周股票复盘：羚锐制药（600285）羚锐集团质押3735万股占总股本6.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621799954","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621799954?lang=zh_cn&edition=full","pubTime":"2026-03-22 02:57","pubTimestamp":1774119428,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，羚锐制药报收于22.49元，较上周的22.05元上涨2.0%。本周，羚锐制药3月20日盘中最高价报22.9元。本周关注点公司公告汇总：羚锐集团质押3735万股，占其所持股份30.66%，占公司总股本6.59%公司公告汇总羚锐制药关于大股东部分股份质押的公告河南羚锐集团有限公司持有羚锐制药股份121,817,898股，占公司总股本的21.48%。质押股份未用于重大资产重组业绩补偿等担保。羚锐集团及其一致行动人合计持股127,813,609股，累计质押37,350,000股，占公司总股本的6.59%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200000788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","BK0070","BK0239","600285"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620439812","title":"羚锐制药（600285）披露大股东部分股份质押公告，3月19日股价下跌0.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620439812","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620439812?lang=zh_cn&edition=full","pubTime":"2026-03-19 17:06","pubTimestamp":1773911165,"startTime":"0","endTime":"0","summary":"截至2026年3月19日收盘，羚锐制药报收于22.04元，较前一交易日下跌0.63%，最新总市值为124.99亿元。该股当日开盘22.02元，最高22.24元，最低21.89元，成交额达1.3亿元，换手率为1.04%。近日，羚锐制药发布《关于大股东部分股份质押的公告》。公告显示，河南羚锐集团有限公司持有公司股份121,817,898股，占公司总股本的21.48%。本次质押7,300,000股后，累计质押股份37,350,000股，占其所持股份比例为30.66%，占公司总股本的6.59%。质押股份未用于重大资产重组业绩补偿等担保。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031900027336.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","BK0070","600285","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604234189","title":"每周股票复盘：羚锐制药（600285）大股东质押股份用于经营周转","url":"https://stock-news.laohu8.com/highlight/detail?id=2604234189","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604234189?lang=zh_cn&edition=full","pubTime":"2026-01-18 03:01","pubTimestamp":1768676472,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，羚锐制药报收于20.94元，较上周的21.28元下跌1.6%。公司公告汇总羚锐制药关于大股东部分股份质押的公告河南羚锐集团有限公司持有公司21.48%股份，本次质押1,700,000股，占其持股比例1.40%，占公司总股本0.30%。质押股份未用于重大资产重组业绩补偿等担保。羚锐集团及其一致行动人合计持股22.54%，累计质押股份占公司总股本5.30%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","600285","BK0188","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603692191","title":"羚锐制药（600285）股东河南羚锐集团有限公司质押170万股，占总股本0.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603692191","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603692191?lang=zh_cn&edition=full","pubTime":"2026-01-14 18:30","pubTimestamp":1768386654,"startTime":"0","endTime":"0","summary":"证券之星消息，羚锐制药1月14日公开信息显示，股东河南羚锐集团有限公司向中国农业银行股份有限公司新县支行合计质押170.0万股，占总股本0.3%。质押详情见下表：截止本公告日，股东河南羚锐集团有限公司已累计质押股份3005.0万股，占其持股总数的24.67%。羚锐制药主营业务：药品的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400033983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600285","BK0070","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601894000","title":"羚锐制药（600285）发布“提质增效重回报”行动方案，1月5日股价上涨4.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601894000","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601894000?lang=zh_cn&edition=full","pubTime":"2026-01-05 18:10","pubTimestamp":1767607823,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，羚锐制药报收于21.72元，较前一交易日上涨4.88%，最新总市值为123.18亿元。该股当日开盘21.3元，最高21.87元，最低21.18元，成交额达3.45亿元，换手率为2.83%。近日，羚锐制药披露了《“提质增效重回报”行动方案》。公告显示，公司为贯彻落实提高上市公司质量的相关要求，制定该行动方案。方案还提出建立长效回报机制，持续实施现金分红，并严格信息披露，提升透明度，加强投资者关系管理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500027791.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600285","BK0070","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2600627036","title":"每周股票复盘：羚锐制药（600285）推“提质增效重回报”行动方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2600627036","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600627036?lang=zh_cn&edition=full","pubTime":"2026-01-02 02:58","pubTimestamp":1767293890,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，羚锐制药报收于20.99元，较上周的21.34元下跌1.64%。本周，羚锐制药12月22日盘中最高价报21.38元。本周关注点公司公告汇总：羚锐制药发布“提质增效重回报”行动方案，强化贴膏剂市场地位。辞职报告自送达董事会之日起生效。羚锐制药关于“提质增效重回报”行动方案的公告河南羚锐制药股份有限公司为贯彻落实提高上市公司质量的相关要求，制定《“提质增效重回报”行动方案》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","BK0070","BK0239","600285"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595535713","title":"羚锐制药（600285）披露高级管理人员辞职公告，12月30日股价上涨1.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595535713","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595535713?lang=zh_cn&edition=full","pubTime":"2025-12-30 22:41","pubTimestamp":1767105674,"startTime":"0","endTime":"0","summary":"截至2025年12月30日收盘，羚锐制药报收于20.74元，较前一交易日上涨1.07%，最新总市值为117.62亿元。公司近日发布公告称，河南羚锐制药股份有限公司董事会于近日收到副总经理武惠斌先生提交的辞职报告，其因公司内部工作调整，申请辞去公司副总经理职务。辞职报告自送达董事会之日起生效。截至公告日，武惠斌先生持有公司股份764,500股，占公司总股本的0.13%，将严格遵守相关减持规定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000044592.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","BK0188","BK0077","600285"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1781937753179,"stockEarnings":[{"period":"1week","weight":-0.0257},{"period":"1month","weight":-0.0395},{"period":"3month","weight":-0.0583},{"period":"6month","weight":-0.0076},{"period":"1year","weight":-0.0634},{"period":"ytd","weight":0.0226}],"compareEarnings":[{"period":"1week","weight":0.026},{"period":"1month","weight":-0.019},{"period":"3month","weight":0.0337},{"period":"6month","weight":0.0514},{"period":"1year","weight":0.2071},{"period":"ytd","weight":0.0306}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"河南羚锐制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"42365人(较上一季度减少1.10%)","perCapita":"13371股","listingDate":"2000-10-18","address":"河南省信阳市新县将军路666号","registeredCapital":"56711万元","survey":" 河南羚锐制药股份有限公司的主营业务是药品的研发、生产及销售。公司的主要产品是贴剂、片剂、胶囊剂、软膏剂。2025年，公司入选“2024年度中国医药工业百强榜”。","listedPrice":8.3},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"羚锐制药(600285)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供羚锐制药(600285)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"羚锐制药,600285,羚锐制药股票,羚锐制药股票老虎,羚锐制药股票老虎国际,羚锐制药行情,羚锐制药股票行情,羚锐制药股价,羚锐制药股市,羚锐制药股票价格,羚锐制药股票交易,羚锐制药股票购买,羚锐制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"羚锐制药(600285)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供羚锐制药(600285)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}